The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6–16 years of age. This approval was based on study data from a Phase 3 clinical trial examining the antihypertensive effects of Benicar in pediatric patients. Benicar was demonstrated to be safe and efficacious in children ages 6–16 with hypertension, resulting in blood pressure reductions that were statistically different in comparison to placebo.

Benicar is an angiotensin II receptor blocker (ARB) already indicated for the treatment of hypertension in adults. Benicar may be used as initial therapy.

For more information call (877) 437-7763 or visit